<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732704</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0004</org_study_id>
    <secondary_id>P02C320_JV06EFS_CIP</secondary_id>
    <secondary_id>CA-0002 EU</secondary_id>
    <secondary_id>CA-0002 Germany</secondary_id>
    <secondary_id>CA-0011</secondary_id>
    <nct_id>NCT02732704</nct_id>
  </id_info>
  <brief_title>THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study</brief_title>
  <official_title>THE ALIGN-AR TRIAL: Safety and Effectiveness/Performance of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect information about treatment for severe Aortic Regurgitation (AR), which affects&#xD;
      the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the&#xD;
      heart does not close tightly and allows some blood to leak back into the heart chamber.&#xD;
      Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred&#xD;
      treatment for severe aortic regurgitation is aortic valve replacement surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a&#xD;
      minimally invasive procedure designed to replace the aortic valve inside the heart. In this&#xD;
      study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended&#xD;
      to help treat severe aortic regurgitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>All-Cause mortality within the first 30 days post index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30 days</time_frame>
    <description>Absence of procedural mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-Procedural Myocardial Infarction</measure>
    <time_frame>At ≤72hr after the index procedure</time_frame>
    <description>Peri-procedural and spontaneous myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke-Free Survival</measure>
    <time_frame>At 30 days and 1 year</time_frame>
    <description>Disabling or non-disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding &amp; Vascular Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Major and minor bleeding</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aortic Regurgitation</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with severe aortic regurgitation (AR).&#xD;
&#xD;
          -  Patient at high risk for open surgical valve replacement&#xD;
&#xD;
          -  Patient symptomatic according to NYHA functional class II or higher&#xD;
&#xD;
          -  The study patient has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital uni or bicuspid aortic valve morphology&#xD;
&#xD;
          -  Previous prosthetic aortic valve (bioprosthesis or mechanical) implant&#xD;
&#xD;
          -  Endocarditis or other active infection&#xD;
&#xD;
          -  Need for urgent or emergent TAVR procedure for any reason&#xD;
&#xD;
          -  Cardiogenic shock or hemodynamic instability requiring inotropic support or&#xD;
             ventricular assist device&#xD;
&#xD;
          -  Severe mitral regurgitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B. Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten P. Vahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod H. Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Baldus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum der Universität zu Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/ Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik GmbH Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60323</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3062</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Disease</keyword>
  <keyword>Aortic Regurgitation</keyword>
  <keyword>Aortic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

